SCHEDULE: Wasatch Advisors Updates Sangamo Therapeutics Stake

Wasatch Advisors LP filed an Amendment No. 9 to Schedule 13G, reporting a 2.1% beneficial ownership stake in Sangamo Therapeutics Inc. as of September 30, 2025.

Summary

• Wasatch Advisors LP, an investment adviser, filed an Amendment No. 9 to its Schedule 13G for Sangamo Therapeutics Inc.
• The filing reports beneficial ownership of 6,188,358 shares of Sangamo Therapeutics Inc. common stock.
• This represents 2.1% of the class of securities.
• Wasatch Advisors LP holds sole voting power over 5,587,777 shares and sole dispositive power over 6,188,358 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: This is a neutral filing, simply reporting a passive ownership stake. It provides no new operational or financial information about the issuer, Sangamo Therapeutics Inc., that would significantly alter sentiment.

Positives

• Wasatch Advisors LP maintains a significant, albeit passive, stake in Sangamo Therapeutics Inc., indicating continued investment interest.

Negatives

• The reported ownership percentage of 2.1% is below the 5% threshold typically associated with more influential institutional stakes, suggesting a smaller, passive position.

Risks

• No specific risks related to Sangamo Therapeutics Inc. are detailed in this Schedule 13G filing, as it primarily reports ownership.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Sangamo Therapeutics Inc.'s future outlook, as its purpose is solely to report beneficial ownership.

Industry Context

This filing reflects a routine disclosure of institutional ownership by an investment adviser in a biotechnology company. It does not provide specific insights into broader industry trends or competitive positioning beyond indicating continued investment in the sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming Wasatch Advisors LP's continued, passive investment.

Key Dates

Keywords

Sangamo Therapeutics, Wasatch Advisors, Schedule 13G, Common Stock, Institutional Ownership, Biotechnology, Gene Therapy